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ABSTRACT
ObjeCtive
To assess whether non-clinical staff can effectively 
manage people at high risk of cardiovascular disease 
using digital health technologies.
Design
Pragmatic, multicentre, randomised controlled trial.
setting
42 general practices in three areas of England.
PartiCiPants
Between 3 December 2012 and 23 July 2013 we 
recruited 641 adults aged 40 to 74 years with a 10 year 
cardiovascular disease risk of 20% or more, no 
previous cardiovascular event, at least one modifiable 
risk factor (systolic blood pressure ≥140 mm Hg, body 
mass index ≥30, current smoker), and access to a 
telephone, the internet, and email. Participants were 
individually allocated to intervention (n=325) or 
control (n=316) groups using automated 
randomisation stratified by site, minimised by practice 
and baseline risk score.
interventiOns
Intervention was the Healthlines service (alongside 
usual care), comprising regular telephone calls from 
trained lay health advisors following scripts generated 
by interactive software. Advisors facilitated self 
management by supporting participants to use online 
resources to reduce risk factors, and sought to 
optimise drug use, improve treatment adherence, and 
encourage healthier lifestyles. The control group 
comprised usual care alone.
Main OutCOMe Measures
The primary outcome was the proportion of 
participants responding to treatment, defined as 
maintaining or reducing their cardiovascular risk after 
12 months. Outcomes were collected six and 12 
months after randomisation and analysed masked. 
Participants were not masked.
results
50% (148/295) of participants in the intervention 
group responded to treatment compared with 43% 
(124/291) in the control group (adjusted odds ratio 1.3, 
95% confidence interval 1.0 to 1.9; number needed to 
treat=13); a difference possibly due to chance 
(P=0.08). The intervention was associated with 
reductions in blood pressure (difference in mean 
systolic −2.7 mm Hg (95% confidence interval −4.7 to 
−0.6 mm Hg), mean diastolic −2.8 (−4.0 to −1.6 mm Hg); 
weight −1.0 kg (−1.8 to −0.3 kg), and body mass index 
−0.4 ( −0.6 to −0.1) but not cholesterol −0.1 (−0.2 to 
0.0), smoking status (adjusted odds ratio 0.4, 0.2 to 
1.0), or overall cardiovascular risk as a continuous 
measure (−0.4, −1.2 to 0.3)). The intervention was 
associated with improvements in diet, physical 
activity, drug adherence, and satisfaction with access 
to care, treatment received, and care coordination. 
One serious related adverse event occurred, when a 
participant was admitted to hospital with low blood 
pressure.
COnClusiOns
This evidence based telehealth approach was 
associated with small clinical benefits for a minority of 
people with high cardiovascular risk, and there was no 
overall improvement in average risk. The Healthlines 
service was, however, associated with improvements 
in some risk behaviours, and in perceptions of support 
and access to care.
trial registratiOn
Current Controlled Trials ISRCTN 27508731.
Introduction
The growing prevalence of long term conditions means 
that new and more efficient approaches to healthcare 
delivery are needed that support people to manage 
their own care, with less reliance on consultations with 
expensively trained healthcare professionals. Effective 
self management, as part of a shift in the management 
of long term conditions, can help improve health out-
comes and reduce costs.1 2  Many countries are explor-
ing a greater use of technologies, such as the internet, 
WhAT IS AlReAdy knoWn on ThIS TopIC
Given the increasing prevalence of long term health conditions, it is necessary to 
explore new ways to deliver healthcare and to support self management to expand 
provision of care at low cost
There is considerable optimism among policy makers that greater use of digital 
health technologies (“telehealth”) in combination with new ways of working could 
transform healthcare delivery, helping the UK national health service to be 
sustainable
Evidence about the effectiveness of telehealth interventions is equivocal, with 
some benefits from specific technologies but little evidence of effectiveness in real 
world implementation
WhAT ThIS STudy AddS
Some evidence suggests that an intervention combining the use of a range of 
digital health technologies with telephone support from trained lay health advisors, 
leads to a modest improvement in overall cardiovascular risk for a minority of 
participants
The intervention had no impact on average cardiovascular risk but was associated 
with improvements in specific cardiovascular risk factors and health behaviours 
and patient perceptions of support and access to care
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remote monitoring, and telephone support as a way of 
expanding provision and increasing access to care for a 
large number of people at relatively low cost. In the 
United Kingdom, current policy envisages these “tele-
health” approaches as having potential to transform the 
delivery of healthcare to make the national health ser-
vice sustainable for the future.3  In the United States, the 
Veterans Health Administration has enrolled more than 
50 000 people in a home telehealth programme,4 5  and 
in Europe the Renewing Health Consortium is evaluat-
ing telehealth programmes in nine countries.6
The volume of literature on the effectiveness of spe-
cific telehealth interventions is burgeoning, with prom-
ising effects for some applications. However, recent 
reviews have highlighted that much of the evidence is of 
poor quality; results are inconsistent; there is a lack of 
theoretical underpinning, which makes it difficult to 
interpret the mixed results; and there is some evidence 
of publication bias in favour of positive results.7-10  Fur-
thermore, focusing on specific applications or 
 technologies in isolation is of limited value since they 
need to be considered in the context of their implemen-
tation within the healthcare system. In practice, large 
scale healthcare programmes based on telehealth 
involve the combined use of technologies—for example, 
online programmes or remote monitoring with tele-
phone support from advisors following computerised 
algorithms. In the recent five year strategic plan for the 
NHS, it is argued that evaluation is needed of “combina-
torial innovation,” in which a range of technologies are 
provided in combination with new ways of working.11 12 
Few rigorous pragmatic studies have been done on 
implementation of this approach in the real world.8 
Furthermore, a key aspect of the argument for tele-
health is increased efficiency, but there are few studies 
incorporating economic analyses, and the limited evi-
dence available suggests that many telehealth interven-
tions are not cost effective.13
We conducted a research programme to develop a 
conceptual model for the effective use of telehealth in 
long term conditions, based on literature reviews,14 15 
qualitative research,16  and surveys of patients’ views.17 
Designated the telehealth in chronic disease (TECH) 
model, this builds on existing approaches such as the 
chronic care model by creating a framework for improv-
ing the management of chronic diseases through tele-
health.18  We used this model to design the Healthlines 
service for the management of long term conditions, 
based on the combined use of internet based health 
applications that had evidence of effectiveness sup-
ported by non-clinically qualified staff working using 
tailored computerised algorithms.19
We evaluated the Healthlines service through linked 
pragmatic multicentre randomised controlled trials 
with nested process and economic evaluations in two 
exemplar conditions: depression and increased cardio-
vascular risk. This paper reports the findings for 
patients with an increased cardiovascular risk. 
Although hypertension, obesity, and hyperlipidaemia 
are often considered as long term conditions, it is more 
appropriate to consider them as risk factors, with their 
combined effect determining overall cardiovascular 
risk.20  This was considered an appropriate exemplar 
because of the high number of people affected (10% of 
adults aged 35-74 in England and Wales have a 10 year 
cardiovascular risk ≥20%),21  which has serious health 
consequences as a result of heart attacks, strokes, kid-
ney disease, and other problems. Cardiovascular dis-
ease causes 28% of deaths in England, accounts for 
10% of all hospital admissions, and involves an annual 
expenditure in England of almost £7bn.22 A low cost 
intervention that could be made widely available to 
large numbers of people could have a beneficial impact 
at a population level even if the effect for an individual 
was small.
Evidence exists for the effectiveness of specific rele-
vant technological approaches, such as home blood 
pressure monitoring,23  mobile phone applications to 
support smoking cessation,24  and online interventions 
for weight loss.25  This evidence provided a good basis 
for the hypothesis that combining these “active 
 ingredients” and implementing them within a new tele-
health model of care would be effective and cost effec-
tive. Furthermore, the introduction in 2008 of the NHS 
Health Check programme was likely to identify a large 
number of people at high cardiovascular risk, and there 
was a need to explore ways to expand provision of care 
to manage them once they had been identified.26
Our hypothesis was that the Healthlines service for 
patients with high cardiovascular risk would be more 
clinically effective and cost effective than usual care, 
while also improving participant’s quality of life, risk 
behaviours, and experience of care.
Methods
Design
This was a pragmatic, multicentre, randomised con-
trolled trial comparing the Healthlines service in addi-
tion to usual care versus usual care alone in adults with 
a high risk of cardiovascular disease. The study was 
registered before recruitment of the first participant, 
and the study protocol has been published.19  After the 
trial commenced there were no important changes to 
the methods, apart from the addition of a nested sub-
study of different forms of information in the patient 
invitation to assess the impact on participant recruit-
ment rates. This did not alter the design or outcomes for 
the main trial; results of this substudy are published 
elsewhere.27
Participants
Patients eligible for the trial were aged between 40 and 
74 years, had a risk of a cardiovascular event in the next 
10 years of 20% or more calculated using the QRISK2 
score,21 and had one or more of the following modifiable 
risk factors (systolic blood pressure ≥140 mm Hg, body 
mass index ≥30, being a current smoker, or any combi-
nation of these). Participants required access to a tele-
phone, the internet, and an email address. We excluded 
people who had a previous cardiovascular event; were 
pregnant or planning pregnancy; had a serious mental 
health problem, dementia, severe learning disability, or 
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substance dependency; were receiving palliative care; 
or were unable to communicate verbally in English.
Participants were recruited from 42 general practices 
covering populations with a range of sociodemographic 
characteristics in and around Bristol, Sheffield, and 
Southampton, England. We used patients’ medical 
records to identify those who had at least one modifi-
able risk factor and estimated 10 year cardiovascular 
risk of 18% or more (we were over-inclusive at the initial 
screening stage because QRISK2 scores based on histor-
ical records may not reflect current risk and we wanted 
to invite potentially eligible people to have an updated 
risk assessment). A random sample of these potentially 
eligible patients in each practice was sent information 
about the study by post, after general practitioners 
screened the list for patients with known exclusion cri-
teria. We sent information to between 250 and 285 
patients in each practice, altering the sampling fraction 
over time to achieve our recruitment targets. A 
researcher telephoned patients who expressed an 
 interest in the study to conduct initial eligibility screen-
ing and then invited them for an assessment of cardio-
vascular risk status by a practice nurse at their 
participating general practice. The nurse measured the 
patients’ blood pressure, weight and height, smoking 
status, and total cholesterol to high density lipoprotein 
cholesterol ratio, and collected all other relevant infor-
mation needed to calculate the patient’s QRISK2 score 
(see supplementary appendix 1). Patients who had a 
QRISK2 score of 20% or more and had one or more of 
the specified modifiable risk factors completed a base-
line questionnaire and consent form, either online or by 
post.
intervention and control
Participants in the control group could continue to 
receive all care normally provided by the NHS, but had 
no contact with the Healthlines service. Usual care 
involved management of cardiovascular risk factors by 
primary care clinicians, including, in some cases, refer-
ral to community services for advice about smoking 
cessation and weight management.
Participants in the intervention arm received support 
from the Healthlines service in addition to usual NHS 
care. The Healthlines service is a multifaceted interven-
tion, incorporating a range of strategies to address the 
various components of the TECH model (see box 1).18 
The intervention is based around regular telephone 
calls from a health advisor, supported by patient spe-
cific tailored algorithms and standardised scripts gener-
ated through a computerised behavioural management 
programme. This programme was originally developed 
and successfully evaluated in the United States by 
Bosworth et al and includes a series of modules on sub-
jects such as drug adherence, diet, and smoking cessa-
tion.28 29  The standardised scripts generated by the 
software were based on recognised principles for 
behaviour change, such as stimulus control, problem 
solving, cognitive restructuring, and goal setting.30 We 
modified the programme to reflect English management 
guidelines and referral options, wrote additional mod-
ules with new content, and adapted the language to suit 
an English population.
For the initial assessment, health advisors contacted 
each participant by telephone to discuss their health 
needs and to agree on specific goals. After the initial 
call, the advisors telephoned each participant approxi-
mately every month for one year. The software was 
interactive and provided different computerised scripts 
so that the content of each call was tailored to meet 
each participant’s particular needs and goals. The soft-
ware provided health advisors with links to relevant 
and quality assured online resources and applications 
to support self management (for example, to help with 
losing weight or stopping smoking), and the advisors 
sent these links to participants by email or post. To 
avoid an anonymous “call centre” approach, the same 
advisor telephoned each participant on each occasion 
when possible, since our earlier qualitative research 
had identified a relationship with the advisor as an 
important factor in engaging prospective participants.15 
The Healthlines service was designed to improve access 
to care and was available until 8 pm on weekdays and 2 
pm on Saturdays.
Participants were also provided with access to a 
Healthlines web portal where they could obtain further 
information about cardiovascular disease, access other 
box 1: Components of the Healthlines cardiovascular disease risk intervention, 
reflecting the teCH conceptual model, with examples of strategies
Computerised behaviour management programme, providing interactive scripts used 
by health advisors
Modules include:
•	Knowledge about cardiovascular risk and healthy lifestyles
•	Review of drugs and side effects
•	Optimisation of drugs for blood pressure lowering
•	Home blood pressure monitoring
•	Review of statins
•	Support for drug adherence
•	Smoking and nicotine replacement therapy
•	Healthy eating
•	Weight loss and Orlistat
•	Alcohol use
•	Exercise
Motivational interviewing. All health advisors were trained in motivational 
interviewing
Self monitoring and feedback—for example, blood pressure online self monitoring 
programme with automated feedback
Treatment optimisation and intensification—health advisors monitor treatment 
response, and send emails to clinicians to intensify treatment when necessary, along 
with reminders of treatment guidelines
Addressing drug adherence—monthly review, scripts incorporated evidence based 
strategies to promote adherence
Improving care coordination—sharing all information sent to clinicians with patients
Supporting primary care—all aspects of the intervention designed to support rather 
than duplicate primary care
Strategies to promote engagement of patients—through continuity of care with the 
same advisor; providing technical support with getting online
Strategies to promote engagement of primary care clinicians—emphasising the 
evidence based nature of intervention components and how it can support their work 
in primary care.
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online resources, request a call-back from Healthlines 
staff, see copies of letters to their general practitioner, 
and use a blood pressure self monitoring system. Partic-
ipants with a baseline systolic blood pressure of 140 
mm Hg or more were offered a validated home blood 
pressure monitor (Omron, M3) by their practice nurse, 
requested to take their blood pressure twice daily for 
the first week and weekly thereafter, and to upload their 
readings to the Healthlines portal. The portal calculated 
average readings over the previous six days initially and 
thereafter over the previous six weeks. Using these 
readings, participants were automatically advised by 
the portal whether their blood pressure was within their 
target, when to take their blood pressure again, and 
what to do if their blood pressure was too high or too 
low. Target blood pressure was based on UK 
 guidelines,31 although an individual’s target could be 
modified by his or her general practitioner. At each tele-
phone contact, health advisors reviewed average blood 
pressure readings, and participants with above target 
readings were asked to see their doctor to review their 
treatment. Advisors sent an email to the general prac-
tice, attaching details of the patient’s recent blood pres-
sure readings and a summary of guidelines from the 
National Institute for Health and Care Excellence about 
recommended steps for intensifying treatment.
The Healthlines advisors were not clinically qualified 
but had experience of working as health advisors for 
NHS Direct and had a further three weeks of training in 
health coaching, motivational interviewing, treatment 
options (including drugs) for hypertension, smoking 
and obesity, and use of the Healthlines computerised 
management programme.
The Healthlines service was originally hosted by NHS 
Direct, which provided a range of telehealth services 
through a network of call centres and a nationally rec-
ognised website. When NHS Direct closed in March 
2014, delivery of the intervention was paused for two 
months while the staff and computer systems were 
transferred to a new provider (Solent NHS Trust). 
Although the Healthlines service resumed unaltered 
after this hiatus, about two thirds of participants expe-
rienced some disruption, and some participants could 
not receive the full number of telephone calls during 
their 12 month follow-up period.
Outcomes
The primary outcome was the proportion of partici-
pants responding positively to treatment, defined as 
maintaining or reducing their 10 year cardiovascular 
risk 12 months after randomisation, estimated using the 
QRISK2 score. Since cardiovascular risk increases with 
age, maintaining or reducing risk over 12 months 
requires an improvement in at least one modifiable risk 
factor. We treated the QRISK2 score (continuous) as a 
secondary outcome. The estimate of risk was based on 
data collected at an assessment by a nurse or healthcare 
assistant at the participant’s general practice at six and 
12 months after recruitment using the same procedures 
as used at baseline (see supplementary appendix 1). 
We calculated follow-up QRISK2 scores by updating age 
and values for modifiable risk factors only. Other vari-
ables such as diagnoses of atrial fibrillation or diabetes 
were not altered to avoid bias from the greater attention 
paid to participants in the intervention arm.
Cardiovascular risk is a composite outcome, and the 
individual risk factors of blood pressure, weight (and 
body mass index), smoking, and cholesterol level were 
important secondary outcomes. Other secondary out-
comes were quality of life, exercise, diet, satisfaction 
with treatment received and with amount of support 
received, perceived access to care, self management 
skills and self efficacy, drug adherence, health literacy, 
use of telehealth, and perceptions of care coordination. 
Table 6 lists the specific measurement instruments used. 
Secondary outcome measures were collected through 
patient questionnaires, completed online or by post at 
baseline and six and 12 months after randomisation. We 
obtained data about prescriptions and primary care con-
sultations from general practice records and details on 
use of the intervention from Healthlines records. Poten-
tial serious adverse events were identified through 
reports from participants or health professionals, fur-
ther inquiry about hospital admissions reported in out-
come questionnaires, or admissions, deaths, or other 
potential serious adverse events identified through 
review of primary care notes at the end of the trial. We 
logged all such events with a description of the event 
and an assessment of expectedness, relatedness, and 
seriousness and we reported to the trial monitoring com-
mittee, sponsor, and ethics committee as appropriate.
sample size
The sample size was chosen pragmatically, taking into 
account the size of effect that would be likely to influ-
ence practice and might be feasible to detect in a trial of 
reasonable size. Based on a previous study we assumed 
that 35% of participants in the control arm would main-
tain or reduce their cardiovascular risk over 12 months.32 
Including 240 participants in each trial arm for analysis 
would provide 80% power (5% α) and 90% power (1% α) 
to detect differences of 13 and 18 percentage points, 
respectively. Assuming 20% attrition, we therefore 
aimed to recruit 600 participants, 300 in each trial arm.
randomisation and masking
Participants who provided consent were randomly allo-
cated in 1:1 ratio to the intervention or usual care group. 
Allocation was made using a web randomisation sys-
tem hosted by the Bristol Randomised Controlled Trials 
Collaboration, and automated to ensure concealment. 
Randomisation was stratified by location of recruitment 
(Bristol, Sheffield, or Southampton) and minimised by 
general practice and baseline QRISK2 score. Research-
ers notified the participants of their allocation by email. 
Participants were not masked to treatment allocation. 
Practice nurses or healthcare assistants collected data 
for the QRISK2 score and may have been aware of treat-
ment allocation at follow-up, but the variables of rele-
vance on smoking (validated using a carbon monoxide 
monitor), blood pressure, and cholesterol level were all 
based on objective quantitative data. All other outcome 
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data were collected by participant self report or elec-
tronic download from medical records and were entered 
and analysed blinded to treatment allocation.
statistical analysis
Analysis was conducted according to CONSORT guide-
lines, following an analysis plan agreed in advance with 
the independent trial steering committee and data mon-
itoring committee. We used descriptive statistics to com-
pare baseline characteristics of trial participants by 
allocated arm. The primary analysis of response to treat-
ment after 12 months was conducted using a mixed 
effects logistic regression model adjusted for site, base-
line QRISK2 score, and general practice (as a random 
effect). Participants were analysed according to  allocated 
arm. We conducted sensitivity analyses of the primary 
outcome using: the assumption that all participants were 
exactly one year older at 12 months’  follow-up, simple 
imputation of missing outcome data that assumed no 
treatment response, multiple imputation of missing 
data, exclusion of general practitioner’s practice as a 
random effect, and adjustment by time between rando-
misation and follow-up. By fitting interaction terms 
between trial arm and subgroup variables, we investi-
gated whether any effect of the Healthlines intervention 
on the primary outcome differed according to subgroups 
defined by sex, age, baseline QRISK2 score, and presence 
or absence of each of the modifiable risk factors (hyper-
tension, obesity, smoking) at baseline.
In secondary analysis of the primary outcome, we 
estimated the complier average causal effect of the 
Healthlines intervention when received as intended. We 
described compliance as little or none (two or fewer 
telephone calls), partial (three to 11 calls), or full (12 or 
13 calls). We estimated the complier average causal 
effect at 12 months using principal stratification in two 
ways: classifying partial compliers as either non-com-
pliers or full compliers.33
Secondary outcomes were analysed in a similar man-
ner to the primary outcome. We estimated between 
group effects using linear, logistic, or binomial mixed 
effects regression models, adjusted for stratification 
and minimisation variables and value of the outcome at 
baseline. Participants were analysed as randomised 
without imputation of missing data. To reduce the num-
ber of statistical comparisons, we estimated between 
group differences for secondary outcomes (other than 
cardiovascular risk factors) only at the final 12 month 
follow-up time point. We described serious adverse 
events by study arm.
We assessed the cost effectiveness of the Healthlines 
intervention from an NHS perspective at 12 months from 
randomisation. Cost effectiveness was not listed as a 
secondary outcome in the trial registry because we 
viewed it as an approach to analysis rather than as an 
outcome; however, assessment of cost effectiveness was 
specified a priori as an aim in the registry and described 
in the published protocol. The methods and results of 
the economic evaluation will be described in detail else-
where. In brief, we compared health system costs with 
incremental quality adjusted life years, measured using 
the EQ-5D-5L generic quality of life questionnaire34 at 
baseline and six and 12 months post-randomisation, to 
produce an estimate of net monetary benefit. We also 
developed a cohort simulation model in order to esti-
mate the cost effectiveness of the intervention over the 
estimated remaining lifetime of trial participants.
All analyses were conducted using Stata version 13 
MP2. The trial was registered prospectively with Current 
Controlled Trials (ISRCTN 27508731).
Patient involvement
There was strong and valuable patient and public 
involvement throughout the Healthlines research 
 programme. Two service user groups (Mental Health 
Research Network and NHS Direct user group) provided 
feedback on the initial questionnaire about patients’ 
preferences and needs in relation to telehealth, which 
helped to inform the intervention design.17  Two repre-
sentatives of these groups became members of the man-
agement group for the five year research programme. 
They contributed to the design of the patient survey,17 
participated in a workshop to develop the TECH model 
that underlies the intervention,18  and became members 
of the trial steering committee for the randomised trial.19 
They commented on the acceptability of the intervention 
to potential participants and obtained feedback from 
their user groups on the outcome measures. At the end of 
the trial they contributed to a workshop of key stakehold-
ers, which was held to discuss interpretation and dissem-
ination of the findings. They also provided useful 
feedback on the final report of the programme, and in 
particular the lay summary. We have thanked all partici-
pants for their involvement and given them details of the 
website where all published results will be made publi-
cally available (www.bristol.ac.uk/healthlines/).
Results
Participants were recruited between 3 December 2012 
and 23 July 2013. Of 7582 people sent information about 
the study, 1205 (16%) expressed interest and were 
assessed. Of these, 641 were eligible and randomly allo-
cated to the Healthlines intervention (n=325) or usual 
care (n=316) arms (fig 1). In total, 597 (93%) of the par-
ticipants provided follow-up data after six months’ 
 follow-up and 586 (91%) after 12 months’ follow-up (the 
primary outcome).
Table 1 shows the characteristics of participants in 
the trial. Overall, the participants were at high risk of a 
cardiovascular event (mean 10 year risk 31%) owing to 
combinations of modifiable and non-modifiable risk 
factors. The participants were predominantly white 
men aged more than 60, and at baseline 356 (56%) were 
obese (body mass index ≥30), 450 (70%) had a blood 
pressure of 140 mm Hg or more, and 528 (18%) were cur-
rent smokers. The two trial arms were well balanced 
except that there were fewer smokers and more partici-
pants with diabetes in the intervention arm. These fac-
tors both contribute to the baseline QRISK2 score, 
which was included as a covariate in all analyses, so we 
did not conduct additional statistical adjustment for 
these imbalances.
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Primary outcome
After 12 months a slightly higher proportion of partici-
pants in the intervention arm had improved or main-
tained their cardiovascular risk compared with those in 
the usual care arm (50% v 42%, respectively; number to 
treat=13), although this apparent difference had wide 
confidence intervals and could be due to chance 
(adjusted odds ratio 1.3, 95% confidence interval 1.0 to 
1.9; P=0.08). This conclusion was largely unchanged in 
our sensitivity analyses (table 2 ). There was no evi-
dence that the intervention was differentially effective 
for any of the prespecified subgroups defined by base-
line characteristics, although the study was not pow-
ered to detect these interaction effects (table 3).
secondary outcomes
Evidence was lacking of any between group difference 
in the proportion of participants who improved or 
maintained their cardiovascular risk after six months’ 
follow-up (table 2 ). There was also no evidence of a dif-
ference between groups in QRISK2 score when treated 
as a continuous measure (table 4 ). However, the 
 intervention was associated with improvements in 
some of the individual modifiable risk factors that con-
tribute to cardiovascular risk, including reductions in 
systolic and diastolic blood pressure and weight and 
body mass index after 12 months’ follow up (table 4 ). 
The  intervention did not lead to improvements in cho-
lesterol levels (table 4 ) or smoking rates (table 5).
Table 6  shows that the intervention was associated 
with improvements in several of the secondary out-
comes. Participants in the intervention arm reported 
that they improved their diets and increased their level 
of exercise. They were more likely to adhere to their 
treatment with statins and antihypertensive drugs. Par-
ticipants in the intervention arm reported improved 
access to care and expressed greater satisfaction with 
the amount of support they received and their overall 
treatment. They also reported that their care was better 
organised and coordinated. For ease of presentation, 
table 6 only shows data on secondary outcomes after 12 
months’ follow-up. Findings after six months are avail-
able from the authors.
After 12 months the incremental cost effectiveness 
ratio was estimated to be £10 859 ($15 600; €13 800) in 
2012/13 prices (incremental cost £138, 95% confidence 
interval £66 to £211; incremental gain in quality 
adjusted life years 0.012, 95% confidence interval 
−0.001 to 0.026). The net monetary benefit at a cost 
effectiveness threshold of £20 000 was estimated to be 
£116 (−£58 to £291). The intervention was likely to be 
cost effective at this threshold after 12 months, with a 
probability of 0.77. The cohort simulation study showed 
that the lifetime cost effectiveness of the intervention 
increased the greater the duration of effect of the inter-
vention on cardiovascular disease risk beyond the fol-
low-up period of the trial. Further details will be 
published elsewhere.
engagement with the intervention
Participants in the intervention arm received a median 
of 10 (interquartile range 8-12) encounters with the 
Healthlines service out of a possible maximum of 13 
encounters. The mean duration of each encounter was 
18 (SD 9.5) minutes. Using a complier average causal 
effect analysis, we explored whether the number of 
encounters received in the intervention arm was associ-
ated with the primary outcome. The results suggest an 
increase in effect of the intervention among partici-
pants who received all or most of the planned number 
of encounters (table 7).
Participants in the intervention arm logged in to the 
Healthlines website on a median of 14 (interquartile 
range 3-47) occasions, more than once a month. Over-
all, 296 (91%) of the participants were given a blood 
pressure monitor, of whom 200 entered at least one 
reading, uploading a median of 70 (48-102) blood pres-
sure readings.
Healthlines advisors sent a median of 5 (2-9) letters 
by email to participants’ doctors. Of these, 138/310 of 
the participants’ doctors were sent letters advising com-
mencement or review of blood pressure drugs, 32 (10%) 
were asked to consider statin treatment, 7 (2%) were 
Oered and received usual care (n=316)Oered and received intervention (n=325):
  In full (n=103; 32%)
  In part (n=194; 60%)
  Little or none (n=26; 8%)
  Missing data (n=2; <1%)
Invited (n=7582)
Assessed for eligibility (n=1205)
Randomised (n=641)
6 month follow-up
Primary outcome measure (based on clinical
  assessment) (n=296; 94%)
Completed questionnaire (n=304; 96%)
Not followed up (n=20; 6%):
  Withdrawn from study (n=6)
  Did not attend assessment (n=13)
  Deceased (n=1)
6 month follow-up
Primary outcome measure (based on clinical
  assessment) (n=301; 93%)
Completed questionnaire (n=308; 95%)
Not followed up (n=24; 7%):
  Withdrawn from study (n=14)
  Did not attend assessment (n=10)
12 month follow-up
Primary outcome measure (based on clinical
  assessment) (n=291; 92%)
Completed questionnaire (n=300; 95%)
Not followed up (n=25; 8%):
  Withdrawn from study (n=11)
  Did not attend assessment (n=13)
  Deceased (n=1)
12 month follow-up
Primary outcome measure (based on clinical
  assessment) (n=295; 91%)
Completed questionnaire (n=300; 92%)
Not followed up (n=30; 9%):
  Withdrawn from study (n=23)
  Did not attend assessment (n=7)
Excluded (n=564):
  Not meeting inclusion criteria (n=449):
    QRISK2<20% (n=187)
    No modiable risks (n=158)
    No internet or email (n=60)
    Any other reason (n=44)
  Declined to participate (n=14)
  Other (n=101)
Excluded (n=6377):
  No response (n=3263)
  Declined to participate (n=2787)
  Other (n=327)
Fig 1 | Flow of participants through trial comparing Healthlines cardiovascular disease 
intervention with usual care
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asked to prescribe orlistat for obesity, and 3 (1%) were 
asked to prescribe drugs to aid smoking cessation. How-
ever, based on data from the medical records, the inter-
vention and control groups did not differ in the number 
of changes in drugs (starting new treatments or 
 changing dose) for hypertension or lipid lowering, with 
a median of 0 (0-1) changes for both types of treatment. 
Similarly, there was no evidence of a difference between 
the arms in the proportion of participants who reported 
taking statins or drugs for hypertension, the proportion 
who had a change in treatment prescribed, or the types 
of drug prescribed (table 8). These data were not speci-
fied as outcomes, but we have presented them to 
explore the mechanism of effect of the intervention.
Over the 12 month period, there was no evidence of a 
difference between the intervention and control arms in 
the number of times participants consulted in primary 
care (mean 11.28 (SD 8.8, n=313) and 11.42 (SD=7.9 
n=325), respectively (adjusted incidence ratio 0.99, 0.89 
to 1.09, P=0.80).
Patient safety
Over the course of the trial, 76 adverse events were 
reported by participants, 38 in each trial arm. Twenty 
four serious and unexpected events occurred in the 
usual care arm and 22 in the intervention arm (see sup-
plementary appendix 2). Only one serious event in the 
intervention arm was likely to be related: a participant 
was admitted to hospital with low blood pressure, 
which could have been due to antihypertensive drugs 
not being reduced after weight loss.
discussion
This study suggests a modest benefit from the Health-
lines service in terms of the proportion of people reduc-
ing or maintaining their cardiovascular disease risk 
over 12 months. Despite the large sample size, the esti-
mate of effect had wide confidence intervals and could 
be consistent with no effect or a 90% increase in the 
odds of reducing or maintaining risk. The results for the 
primary outcome were not statistically significant either 
in the complete case analysis or after multiple imputa-
tion of missing data. Furthermore, there was no evi-
dence of a difference between the trial arms in average 
risk, treating QRISK2 as a continuous measure (a sec-
ondary outcome). Cardiovascular risk is a composite 
measure, based on several underlying risk factors. The 
Healthlines intervention was associated with small but 
meaningful improvements in several of these factors, 
including reductions in blood pressure and weight but 
not in cholesterol level or smoking. It was also associ-
ated with improvements in self management 
behaviours such as diet and physical activity, better 
adherence to drugs, and greater participant satisfaction 
with support, access to care, and treatment received. It 
is important to note that these improvements in self 
management behaviours would reduce cardiovascular 
risk beyond the benefit captured in the QRISK2 score 
and are also likely to reduce risk for many other com-
mon and serious diseases, so our focus on cardiovascu-
lar risk measured using QRISK2 is likely to be 
conservative in terms of estimating overall benefit.
The intervention was not successful at promoting 
optimisation of drug treatment in line with current 
guidelines, which was a key intended mechanism for 
reducing blood pressure and cholesterol levels. This is 
table 1 | baseline characteristics of participants allocated to usual care or Healthlines 
intervention. values are percentages (numbers) unless otherwise stated
Characteristics usual care (n=316) intervention (n=325)
Mean (SD) age at CVD assessment (years) 67.3 (4.7) 67.5 (4.9)
Women 21 (66) 18 (60)
White ethnicity 99 (313) 99 (321)
Current employment situation: n=311 n=316
 Full time 13 (39) 17 (54)
 Part time 14 (43) 9 (29)
 Unemployed 1 (4) 1 (2)
 Unable to work: long term illness/disability 2 (7) 1 (3)
 Unable to work: carer 1 (3) 1 (2)
 Retired 63 (196) 66 (210)
 Homemaker 1 (3) 1 (4)
 Other 5 (16) 4 (12)
Occupation (most recent or current): n=294 n=294
 Administrative or secretarial 11 (31) 10 (29)
 Associate professional or technical 15 (45) 12 (35)
 Elementary* 10 (28) 5 (16)
 Managers or senior officials 19 (55) 22 (65)
 Personal services† 2 (5) 3 (9)
 Process, plant, and machine operatives 5 (15) 6 (17)
 Professionals 19 (57) 22 (64)
 Sales and customer services 4 (11) 4 (13)
 Skilled trades 16 (47) 16 (46)
Highest education qualification: n=307 n=318
 Degree or higher degree 21 (65) 23 (72)
 A levels or equivalent 19 (58) 17 (53)
 GCSEs/O levels or equivalent 45 (137) 43 (136)
 No qualifications 15 (47) 18 (57)
Accommodation: n=315 n=323
 Own accommodation or buying with mortgage 84 (264) 87 (281)
 Part rented or rented 15 (46) 12 (40)
 Live rent-free 2 (5) 1 (2)
 Mean (SD) index of multiple deprivation 16.7 (12.6) 15.5 (11.3)
Clinical data:
 Mean (SD) QRISK2 score 30.8 (9.5) 31.1 (10.2)
 Mean (SD) systolic blood pressure (mm Hg) 148.1 (17.6) 147.6 (16.2)
 Mean (SD) diastolic blood pressure (mm Hg) 80.0 (10.4) 81.2 (9.6)
 Mean weight (SD) 91.9 (18.9) 93.2 (17.3)
 Mean (SD) body mass index 30.9 (5.7) 31.2 (5.4)
 Mean (SD) total cholesterol level (mmol/L) 4.9 (1.2); n=315 4.9 (1.2);n=324
 Mean (SD) total cholesterol: HDL ratio 4.2 (1.4); n=315 4.2 (1.5); n=323
 Smoking status:
  Non-smoker 33 (103) 35 (114)
  Former smoker 47 (148) 50 (163)
  Light smoker 9 (30) 8 (25)
  Moderate smoker 5 (17) 5 (16)
  Heavy smoker 6 (18) 2 (7)
 Taking antihypertensive 61 (193) 64 (209)
 Taking lipid lowering drug 49 (153/312) 49 (158/322)
 Diabetes 20 (62) 24 (77)
 Chronic kidney disease 11 (34) 6 (20)
 Atrial fibrillation 6 (20) 7 (23)
 Rheumatoid arthritis 3 (8) 2 (6)
CVD=cardiovascular disease; GCSE=general certificate of secondary education; HDL=high density lipoprotein 
cholesterol.
*Jobs not needing qualifications, such as cleaners.
†For example, care worker, teaching assistant.
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consistent with previous research highlighting the 
problem of clinical inertia—that treatment is not neces-
sarily intensified in people who fail to reach treatment 
targets even when regular monitoring shows inade-
quate control.35 Although the observed reduction in car-
diovascular risk was small (and could be due to 
chance), the likely reduction in cardiovascular events 
in the longer term means that the Healthlines service 
was likely to be cost effective.
strengths and limitations of this study
This is a large and pragmatic trial of a telehealth inter-
vention to reduce cardiovascular risk. It is a complex 
intervention combining a range of telehealth 
approaches and has a strong theoretical foundation 
based on the underlying telehealth in chronic disease 
(TECH) conceptual model.18 The large sample size and 
high level of participant retention enhance internal 
validity, whereas the multicentre recruitment and 
broad inclusion criteria enhance external validity.
The Healthlines intervention incorporates the use of 
several telehealth approaches, which have reasonable 
evidence of effectiveness, such as home blood pressure 
monitoring, and we sought to implement them on a 
wide scale. Most research studies of telehealth inter-
ventions relate to specific technological innovations 
and can be characterised as efficacy trials, in that they 
demonstrate the effect of a well defined intervention in 
people with tightly defined inclusion and exclusion cri-
teria, and who are motivated to use the particular 
application. These studies may lead to estimates of 
effect that are exaggerated when compared with the 
effects observed with wider implementation of the 
application. By contrast, this trial was pragmatic, test-
ing an intervention as delivered by a mainstream NHS 
provider in a way that could be rolled out quickly on a 
wide scale.
This study has several limitations. Firstly, only 16% of 
those sent information about the study expressed an 
interest in it. This response rate is not unusual in pri-
mary care based trials in which people who may not 
have an expressed health need are invited to take part 
in research. Indeed the response rate in this trial was 
higher than in several other influential trials of related 
interventions.36-38  However, if non-respondents differ 
from respondents because of disinterest in research this 
could reduce the generalisability of the trial findings. 
Based on information from 2741 people who gave a rea-
son for non-participation, the most common reasons 
were related to technology rather than to research: 1491 
(54%) had no internet access and 1225 (45%) did not feel 
confident using computers (people could provide more 
than one reason).39 Many people (n=1135, 41%) did not 
feel they needed additional support with health prob-
lems. It is important to note that less than half of those 
invited for an NHS Health Check actually attend, and 
not everyone who smokes or is overweight is motivated 
to change. We also recognise that telehealth interven-
tions are not necessarily of interest to everyone, and 
take-up in routine service use may be low. However, 
table 2 | improving or maintaining cardiovascular risk as a binary outcome. values are percentages (no/total no) unless stated otherwise
Primary outcome usual care* intervention†
adjusted odds 
ratio (95% Ci) P value
Primary analysis:
 Improved/maintained QRISK2 after 12 months 43 (124/291) 50 (148/295) 1.3 (1.0 to 1.9) 0.08
Secondary analysis:
 Improved/maintained QRISK2 after 6 months 46 (137/296) 48 (145/301) 1.1 (0.8 to 1.5) 0.65
Sensitivity analyses of improved/maintained QRISK2 after 12 months:
 Assuming all participants were one year older 45 (130/291) 52 (153/295) 1.3 (1.0 to 1.9) 0.01
 Simple imputation, assuming missing binary outcome is non-response 40 (124/316) 46 (148/325) 1.3 (0.9 to 1.8) 0.11
 Multiple imputation 44 (139/316) 50 (163/325) 1.3 (0.9 to 1.8) 0.11
 Not including general practice as random effect 43 (124/291) 50 (148/295) 1.3 (1.0 to 1.9) 0.08
 Adjusted by days since randomisation to primary outcome assessment 43 (124/291) 50 (148/295) 1.3 (1.0 to 1.9) 0.09
All analyses adjusted by site (Bristol, Sheffield, or Southampton) and baseline QRISK2 score. Analyses are further adjusted by other covariates if specified. General practice included as random 
effect unless specified otherwise.
*n=296 at six months; n=291 at 12 months; n=316 for imputed data.
†n=301 at six months; n=295 at 12 months; n=325 for imputed data.
table 3 | subgroup analyses of primary outcome
subgroups
improving or maintaining 
QrisK2 at 12 month 
follow-up
adjusted odds 
ratio* (95% Ci)
interaction 
P value
usual care 
(n=291)
intervention 
(n=295)
Baseline CVD assessment age group:
 40-59 54 (7/13) 61 (11/18) 1.5 (0.3 to 6.6)
 60-69 44 (78/177) 49 (75/152) 1.2 (0.8 to 1.9)
 ≥70 39 (39/101) 50 (62/125) 1.6 (0.9 to 2.8) 0.71
Men 46 (105/227) 51 (125/243) 1.2 (0.9 to 1.8)
Women 30 (19/64) 44 (23/52) 1.8 (0.8 to 4.0) 0.37
Baseline QRISK2 score:
 17.3-24.9 37 (37/101) 45 (44/98) 1.4 (0.8 to 2.5)
 25.0-29.9 38 (26/68) 44 (35/79) 1.2 (0.6 to 2.4)
 ≥30.0 50 (61/122) 58 (69/118) 1.4 (0.8 to 2.4) 0.95
Baseline modifiable risk factor:
 Systolic blood pressure <140 mm Hg 33 (30/90) 41 (35/85) 1.5 (0.8 to 2.8)
 Systolic blood pressure ≥140 mm Hg 47 (94/201) 54 (113/210) 1.3 (0.9 to 1.9) 0.73
 Body mass index <30.0 50 (65/131) 52 (67/129) 1.1 (0.6 to 1.8)
 Body mass index ≥30.0 37 (59/160) 49 (81/166) 1.7 (1.1 to 2.6) 0.20
 Current smoker 51 (29/57) 53 (23/43) 1.1 (0.5 to 2.5)
 Not current smoker 41 (95/234) 50 (125/252) 1.4 (1.0 to 2.1) 0.55
All analyses adjusted by site (Bristol, Sheffield, or Southampton), baseline outcome, and baseline QRISK2 score. 
General practice included as random effect.
*Odds ratio comparing intervention with usual care.
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healthcare is likely to be increasingly personalised, 
with different forms of care being chosen by different 
groups in the population. Telehealth interventions may 
be useful for a minority of potential participants if (as in 
the case of increased cardiovascular risk) the total num-
ber of people at risk is large.
Secondly, the closure of NHS Direct towards the end 
of the trial meant that delivery of the intervention was 
disrupted and many participants received less than the 
full course of intervention encounters. However, that 
we were able to move the service quickly to another pro-
vider demonstrates the transferability of the approach. 
Thirdly, we analysed a large number of secondary out-
comes in order to capture the range of potential effects 
from this complex intervention, but this raises the pos-
sibility of some apparent differences being due to 
chance because of multiple testing. Fourthly, the 
 sample size was chosen pragmatically and assumed 
that 35% of participants in the control arm would main-
tain or reduce their cardiovascular risk over 12 months. 
In the trial, a higher than anticipated proportion of 
those in the control group achieved this, perhaps 
because of the impact of the NHS Health Checks pro-
gramme.26 This reduced the power of the study to detect 
differences between the intervention and control 
groups, but this will have been mitigated to some extent 
by the fact that we recruited and successfully followed 
up more patients than anticipated. Fifthly, the study 
was limited to patients aged less than 75 years (because 
this is the age range in which QRISK2 has been vali-
dated and is also the age group targeted by NHS Health 
Checks), but this intervention could potentially also 
help older people. The study also excluded people with-
out access to the internet; however, the proportion of 
the population with access is increasing rapidly.
Finally, the use of cardiovascular risk as a composite 
outcome has limitations because the QRISK2 score is 
strongly dominated by non-modifiable factors such as 
age and sex. We chose to analyse the QRISK2 as a binary 
measure of “response to treatment” for the primary out-
come because this approach is sensitive to changes in 
modifiable risk factors. The number of patients needed 
to treat to gain benefit from the intervention was 13. 
However, because only a minority of participants bene-
fited, there was no statistically significant change in 
QRISK2 averaged across all participants when analysed 
as a continuous variable (a secondary outcome). Never-
theless, the small changes in modifiable risk factors 
observed in this trial are likely to be associated with 
table 5 | secondary outcome: smoking. values are percentages (numbers) unless stated 
otherwise
smoker status usual care* intervention†
adjusted odds 
ratio (95% Ci) P value
Smoker at 6 months:
 Yes 18 (52/296) 15 (45/301)
 No 82 (244/296) 85 (256/301) 0.3 (0.1 to 1.2) 0.01
Smoker at 12 months:
 Yes 18 (52/291) 17 (49/295)
 No 82 (239/291) 83 (246/295) 0.4 (0.2 to 1.0) 0.06
All analyses adjusted by site (Bristol, Sheffield, or Southampton), baseline QRISK2 score, and baseline smoking 
category (non-smoker, former smoker, light smoker, moderate smoker, heavy smoker). General practice included 
as random effect.
*n=296 at six months; n=291 at 12 months.
†n=301 at six months; n=295 at 12 months.
table 4 | secondary outcomes: QrisK2 score as a continuous outcome and individual modifiable cardiovascular risk 
factors of blood pressure, cholesterol level, weight, and body mass index
secondary outcome
usual care* intervention† adjusted 
difference in 
means (95% Ci) P value
unadjusted 
mean (sD) no
unadjusted 
mean (sD) no
QRISK2 score as continuous variable:
 6 months 31.0 (9.5) 296 31.4 (10.3) 301 0.1 (−0.2 to 0.4) 0.49
 12 months 31.2 (10.3) 291 31.3 (10.7) 295 −0.4 (−1.2 to 0.3) 0.27
Systolic blood pressure (mm Hg):
 6 months 141.4 (15.4) 296 141.0 (15.1) 301 0.0 (−1.9 to 1.9) 0.10
 12 months 142.2 (16.1) 291 139.6 (14.0) 295 −2.7 (−4.7 to −0.6) 0.01
Diastolic blood pressure (mm Hg):
 6 months 78.0 (9.7) 296 78.2 (9.9) 301 −0.6 (−1.8 to 0.6) 0.34
 12 months 78.7 (9.9) 291 76.6 (9.2) 295 −2.8 (−4.0 to −1.6) <0.001
Total cholesterol level (mmol/L)‡:
 12 months 4.7 (1.1) 288 4.6 (1.2) 295 −0.1 (−0.2 to 0.0) 0.17
Total cholesterol:HDL ratio:
 12 months 4.0 (1.5) 287 4.0 (1.7) 294 −0.1 (−0.2 to 0.1) 0.45
Weight (kg):
 6 months 91.1 (18.4) 296 91.7 (17.7) 301 −0.9 (−1.5 to −0.2) 0.006
 12 months 91.2 (19.1) 291 91.3 (17.5) 293 −1.0 (−1.8 to −0.3) 0.008
Body mass index (kg/m2):
 6 months 30.6 (5.4) 296 30.7 (5.5) 301 −0.3 (−0.5 to −0.1) 0.006
 12 months 30.8 (5.7) 291 30.5 (5.4) 293 −0.4 (−0.6 to −0.1) 0.008
HDL=high density lipoprotein cholesterol.
All analyses adjusted by site (Bristol, Sheffield, or Southampton), baseline QRISK2 score, and baseline outcome. General practice included as random 
effect.
*n=296 at six months; n=291 at 12 months.
†n=301 at six months; n=295 at 12 months.
‡Cholesterol was not remeasured after six months. Baseline cholesterol measurement was used to calculate QRISK2 at six months.
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meaningful benefits. Based on the systematic review by 
Law et al,40 the reductions in blood pressure observed 
in this trial would lead to a 23% reduction in the relative 
risk of stroke and a 15% reduction in the relative risk of 
a heart attack. The combined effect (along with the 
reduction in weight) suggests that these small changes 
in modifiable risk factors are likely to be worthwhile, 
particularly at a population level when applied to the 
large number of people at high risk of cardiovascular 
disease.
Comparison with other studies
This was a trial of the implementation of the combined 
use of a range of telehealth interventions to deal with 
cardiovascular risk factors. The results are broadly 
consistent with earlier trials, which have studied 
 different components of the intervention in isolation 
to reduce individual risk factors. A systematic review 
of trials of blood pressure self monitoring showed that 
this was associated with small reductions in both sys-
tolic and diastolic blood pressure of a similar size to 
those achieved in the Healthlines cardiovascular dis-
ease risk trial.23  A Cochrane review found that com-
puter based interactive interventions for weight loss 
were associated with a mean weight loss of 1.5 kg (95% 
confidence interval 0.9 to 2.1 kg) compared with no or 
minimal intervention, an effect which is also consis-
tent with our findings.25  Systematic reviews on inter-
net based telehealth interventions for smoking 
cessation show mixed effects, although mobile phone 
based interventions are effective and telephone quit-
lines can improve cessation rates in those people who 
table 7 | Complier average causal effect analysis of primary outcome. values are unadjusted odds ratios (95% confidence 
intervals) unless stated otherwise
amount of intervention 
received (no of encounters)
Maintenance/reduction in QrisK2 at 12 
month follow-up
Partial compliers classified 
as non-compliers
Partial compliers 
classified as full compliers
usual care (n=291) intervention (n=293) intervention v usual care intervention v usual care
None (0-2) 43 (124/291) 29 (4/14)
Partial (3-11) 44 (77/177)
Full (12-13) 65 (66/102) 2.4 (1.4 to 4.3) 1.4 (1.0 to 1.9)
Three participants who never received Healthlines intervention and two participants who only received unscheduled non-encounter calls are 
categorised as receiving none of the intervention. Two intervention arm participants had missing data on encounters.
table 6 | secondary outcomes at 12 month follow-up
secondary outcome
usual care (n=300) intervention (n=300)
adjusted difference 
in means (95% Ci) P value
unadjusted 
mean (sD) no
unadjusted 
mean (sD) no
Quality of life (EQ-5D-5L)34 0.78 (0.2) 297 0.81 (0.2) 295 0.01 (−0.01 to 0.03) 0.41
Patient behaviours:
 Exercise behaviour (heiQ subscale: health directed behaviour’)*44 2.9 (0.8) 294 3.0 (0.8) 297 0.1 (0.0 to 0.2) 0.003
 Diet (starting the conversation questionnaire)*45 10.3 (2.1) 299 10.9 (2.1) 300 0.6 (0.4 to 0.9) <0.001
Patient experience:
 Satisfaction with treatment*† 3.7 (0.8) 215 3.9 (0.7) 244 0.1 (0.0 to 0.3) 0.03
 Satisfaction with amount of support received*† 2.8 (0.6) 207 3.1 (0.5) 260 0.3 (0.2 to 0.4) <0.001
 Perceived access to care*† 5.5 (1.7) 293 5.8 (1.3) 287 0.3 (0.0 to 0.5) 0.02
Self management skills and self efficacy (heiQ):44
 Self monitoring and insight* 3.2 (0.4) 295 3.3 (0.4) 295 0.1 (0.0 to 0.1) 0.07
 Constructive attitudes and approaches* 3.3 (0.5) 296 3.4 (0.5) 295 0.0 (0.0 to 0.1) 0.63
 Skill and technique acquisition* 3.1 (0.5) 297 3.2 (0.5) 295 0.1 (0.1 to 0.2) <0.001
Health services navigation* 3.1 (0.6) 296 3.2 (0.5) 297 0.0 (0.0 to 0.1) 0.27
Drug adherence (Morisky)*:46
 Anti-hypertensives‡ 3.8 (0.5) 194 3.9 (0.3) 203 0.1 (0.0 to 0.2) 0.01
 Statins‡ 3.6 (0.8) 165 3.8 (0.5) 169 0.2 (0.1 to 0.3) 0.005
 Health literacy (eHEALs)*47 3.9 (0.7) 296 4.0 (0.7) 295 0.1 (0.0 to 0.2) 0.13
Care coordination (Haggerty):48
 Role clarity and coordination* 2.9 (0.5) 247 3.0 (0.3) 263 0.1 (0.0 to 0.1) 0.02
 Evidence of care plan* 3.8 (2.1) 209 4.9 (2.0) 236 1.2 (0.8 to 1.5) <0.001
 Overall experience of organisation of healthcare* 3.6 (0.9) 296 3.8 (0.7) 296 0.1 (0.0 to 0.2) 0.04
 Self organisation of healthcare* 3.9 (1.1) 283 3.8 (1.0) 287 −0.1 (−0.2 to 0.1) 0.37
Use of telehealth*†‡:
 Online searching 1.6 (0.7) 297 1.6 (0.7) 296 0.1 (−0.0 to 0.2) 0.10
 Online forum or group 1.1 (0.3) 295 1.1 (0.4) 298 0.0 (−0.0 to 0.1) 0.29
All analyses adjusted by site (Bristol, Sheffield, or Southampton), baseline outcome (if measured), and baseline QRISK2 score. General practice included as random effect.
*Higher score is more positive (less access difficulties, greater satisfaction).
†Based on scales generated before main trial analysis using principal components analysis and incorporating questions taken from existing validated questionnaires or constructed for this 
research.
‡Only applicable to those taking antihypertensives or statins.
§Five level ordered categorical variable (never/almost never to daily/almost daily).
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proactively contact them.24 41 42 It is important to note 
that the above reviews were all based on people who 
had the risk factor of interest, and many trials only 
included those who were motivated to change the spe-
cific risk factor. In the Healthlines cardiovascular dis-
ease risk trial only a proportion of participants had 
raised blood pressure, were obese, or were smokers at 
baseline, and they were not necessarily motivated to 
change the main factor  contributing to their risk, so 
effects are likely to be smaller than in studies on spe-
cific risk factors.
The Healthlines intervention tested in this trial had a 
similar impact on blood pressure reduction as the ear-
lier trials by Bosworth et  al, which used a similar 
behavioural management system (but provided by 
nurses rather than lay staff and without incorporating 
the use of internet resources).28 29  However, the Health-
lines trial had less impact than two trials from the 
United States, which involved blood pressure self man-
agement with pharmacist management of drugs by 
phone or over the internet.36 37 The involvement of phar-
macists to directly alter drugs without the intermediate 
step of sending advice to primary care doctors may be 
associated with more effective optimisation of treat-
ment but could be problematic in a routine primary care 
context, when patients often have comorbidities and 
other factors need to be considered in treatment deci-
sions.
Two systematic reviews of telehealth interventions to 
reduce overall cardiovascular risk have recently been 
published.14 43 Several studies demonstrated small 
improvements in blood pressure and weight, findings 
for cholesterol were equivocal, and there was no evi-
dence of increased rates of smoking cessation. Our 
results are consistent with these findings but provide 
much stronger evidence from a large, rigorous and 
pragmatic trial.
implications for clinicians and for policy
The development of the Healthlines service reflected a 
conceptual framework that was based on promoting 
self management, improving drug adherence and opti-
misation of drug treatment, coordination of care, and 
the active engagement of patients and primary care cli-
nicians.18 This randomised controlled trial shows mod-
est but cost effective benefit in cardiovascular risk 
reduction. Delineating how components of a multifac-
eted intervention work, alone or in combination; their 
effect on doctor practice in terms of optimisation or 
intensification of medicines and their effect on 
behaviour modification by patients is complex. What is 
clear is that patients who engaged with the intervention 
seem to gain the most in terms of cardiovascular risk, 
but some components of the intervention, particularly 
optimisation or intensification of drugs, were ineffec-
tive. To improve the effectiveness of the intervention it 
will be important to target it at those who are motivated 
to change their risk behaviours, and to improve commu-
nication with primary care prescribers about drug treat-
ment recommendations.
Conclusions
Optimism about the potential of telehealth approaches 
to improve the accessibility, convenience, and effi-
ciency of healthcare has been considerable. This study 
adds to the growing evidence base, which suggests that 
healthcare delivery systems based on telehealth may be 
associated with some benefits, although these should 
not be assumed. However, this study has demonstrated 
the feasibility of delivering an intervention on a wide 
table 8 | treatment optimisation: cardiovascular risk related drug prescriptions over trial. values are percentages (numbers) unless stated otherwise
Measure of treatment optimisation usual care (n=316) intervention (n=325)
adjusted odds ratio (95% Ci): 
intervention v usual care P value
Experienced at least one change in drugs over 12 month period*:
 Antihypertensive 32 (100) 38 (123) 1.3† (0.9 to 1.8) 0.12
 Cholesterol drugs, including statins 22 (71) 26 (84) 1.2† (0.8 to 1.7) 0.33
Self reported use of drugs over 12 month period‡:
 Antihypertensive 68 (196/289) 70 (202/287)
 Statin 57 (165/297) 57 (166/290)
Prescribed at least one drug over trial period*:
 Antiplatelet 18 (57) 19 (62)
 Cholesterol drugs, including statins 61 (192) 62 (201)
 Smoking cessation 1 (3) 2 (5)
 Obesity drugs 1 (2) 1 (4)
 Antihypertensive 70 (222) 73 (236)
Prescribed antihypertensive by drug class over trial period*:
 ACE inhibitors or ARBs 50 (159) 52 (170)
 β blockers 18 (58) 16 (52)
 Calcium channel blockers 36 (114) 40 (129)
 Diuretics 29 (90) 29 (93)
 Other 8 (26) 8 (26)
ACE=angiotensin converting enzyme; ARBs=angiotensin receptor blockers.
*Medical records data.
†Only these between treatment group comparisons are analysed because treatment optimisation was a key aspect of the intervention. Analyses are adjusted by site (Bristol, Sheffield, or 
Southampton) and baseline QRISK2 score. General practice included as random effect.
‡Questionnaire data.
doi: 10.1136/bmj.i2647 | BMJ 2016;353:i2647 | the bmj
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scale at relatively low cost and using non-clinically 
trained health advisors supported by computerised 
algorithms. This increases the capacity of the  healthcare 
system to provide an intervention to large numbers of 
people. Further development of this type of interven-
tion is justified to increase the effectiveness of the 
Healthlines service approach.
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